|
2011 NF Conference
June 11-14, 2011
Saturday, June 11
|
7:00 am – 8:00 am:
|
Breakfast
|
SESSION 1: Intracellular Functions of the NF2 Protein, Merlin
Chairs: Marco Giovannini, MD, PhD, House Ear Institute; and Duojia Pan, PhD, Johns Hopkins University
|
8:00 am – 8:30 am:
|
Merlin’s nuclear function
Filippo Giancotti, MD, PhD, Memorial Sloan-Kettering Cancer Center |
|
8:30 am - 9:00 am: |
Merlin and the ERM proteins organize the cortex of single cells
Andrea McClatchey, PhD, Massachusetts General Hospital |
|
9:00 am - 9:30 am: |
Angiomotin: a new player in NF2
Chunling Yi, PhD, The Wistar Institute |
|
9:30 am - 10:00 am: |
The Sterile 20 kinase Tao-1 negatively regulates cell proliferation during development by activating the Hippo tumor suppressor pathway
Julian Boggiano, The University of Chicago |
|
10:00 am - 10:15 am: |
General Discussion |
10:15 am - 10:45 am: Refreshment Break
SESSION 2: Keynote Presentation
|
10:45 am - 11:45 am:
|
Introduction: Nancy Ratner, PhD, Cincinnati Children’s Hospital Medical Center
Molecular biology of sporadic astrocytoma - emerging links to neurofibromatosis
|
|
11:45 am - 11:50 am: |
Schwannomatosis: A Personal Perspective: Jill Beck |
|
11:50 am - 2:30 pm:
|
Lunch and Afternoon on your own
|
SESSION 3: Poster Session 1: Basic Science
Judges: Helen Morrison, PhD, Leibniz Institute for Age Research, Germany; David Largaespada, PhD,
The University of Minnesota; and Yuan Zhu, PhD, University of Michigan
2:30 pm - 4:00 pm
SESSION 4: Panel Discussion 1: Gliomas in Neurofibromatosis
Moderator: Anat Stemmer-Rachamimov, MD, Massachusetts General Hospital
Panelists: Gareth Evans, MD, University of Manchester, United Kingdom; Catherine Nutt, PhD,
Massachusetts General Hospital; and David Gutmann, MD, PhD, Washington University
4:00 pm - 5:30 pm
|
5:30 pm: |
Bus leaves for Diamond Cross Ranch |
|
6:30 pm - 10:00 pm: |
Welcome Dinner and Reception
Offsite at Diamond Cross Ranch |
Sunday, June 12
|
7:00 am - 8:00 am:
|
Breakfast
|
SESSION 5: NF1 Peripheral Nerve Tumorigenesis
Chairs: Wade Clapp, MD, Indiana University
|
8:00 am - 8:30 am:
|
Development of mouse models of NF1-associated progressive peripheral nerve sheath tumor with therapeutic implications
|
|
8:30 am - 9:00 am: |
Novel mouse models for NF1
Alison Lloyd, PhD, University College London, United Kingdom |
|
9:00 am - 9:30 am: |
Current progress in modeling PNS & CNS tumors in NF1
Luis Parada, PhD, University of Texas Southwestern |
|
9:30 am - 10:00 am: |
Transposon-Based, Forward Genetic Screening in Mice Reveals New Pathways for Schwann Cell Tumor Development
David Largaespada, PhD, University of Minnesota |
|
10:00 am - 10:15 am: |
General Discussion |
|
10:15 am - 10:45 am:
|
Refreshment Break
|
SESSION 6: Keynote Presentations
|
10:45 am - 11:45 am:
|
Introduction by: Michel Kalamarides, MD, PhD, Universite Paris 7, France
Whole genome and whole exome sequencing for rare mutation discovery
KeynoteSpeaker: Stan Nelson, MD, David Geffen School of Medicine at UCLA
|
|
11:45 am - 3:30 pm:
|
Lunch and Afternoon on your own
|
|
1:00 pm - 3:00 pm: |
Clinical Coordinator Luncheon: Invite Only |
SESSION 7: Mouse Models of NF2 Tumorigenesis
Chairs: Filippo Giancotti, MD, PhD, Memorial Sloan-Kettering Cancer Center; and
Helen Morrison, PhD, Leibniz Institute for Age Research
|
3:30 pm - 3:35 pm: |
NF2: A Personal Perspective: Shelia Heal |
|
3:35 pm - 4:05 pm:
|
Modulating F-actin organization induces organ growth through the Hippo pathway
|
|
4:05 pm - 4:35 pm: |
Translating NF2 preclinical research into clinical trials
Marco Giovannini, MD, PhD, House Ear Institute |
|
4:35 pm - 5:05 pm: |
The NF2/Merlin tumor suppressor functions through the Hippo pathway to regulate tissue homeostasis in mammals
Duojia Pan, PhD, Johns Hopkins University |
|
5:05 pm - 5:35 pm: |
Insights from mouse models to understand meningiomagenesis
Michel Kalamarides, MD, PhD, Universite Paris 7, France |
5:35 pm - 8:00 pm: Dinner on your own
SESSION 8: Concurrent Abstract Platform Presentations
SESSION 8A: Clincal NF2
Chair: Gareth Evans, MD, University of Manchester, United Kingdom
|
8:00 pm - 8:15 pm:
|
Intratumoral Concentration and Activity of Lapatinib in Human Vestibular Schwannoma
|
|
8:15 pm - 8:30 pm: |
Meningioma response to bevacizumab: A retrospective analysis of treatment results in 14 NF2 patients
Fabio Nunes, MD, Massachusetts General Hospital and Harvard Medical School |
|
8:30 pm - 8:45 pm: |
Characterization of Gallium-Octreotide PET findings in patients with tumors associated with Neurofibromatosis Type 2
Simone Ardern-Holmes, MBChB, FRACP, Children's Hospital at Westmead, Australia |
|
8:45 pm - 9:00 pm: |
The NFTI-QOL: A new disease-specific quality of life score for NF2
Rachael Hornigold, MRCS, Guy's and St. Thomas' NHS Foundation Trust, United Kingdom |
|
9:00 pm - 9:15 pm: |
Relationship between whole body tumor burden and quality of life in patients with NF1, NF2 and schwannomatosis
Vanessa Merker, Massachusetts General Hospital and Harvard Medical School |
|
9:15 pm - 9:30 pm: |
The Schwannomatosis International Database: An Update
Amanda Bergner, CGC, Johns Hopkins Comprehensive Neurofibromatosis Center |
SESSION 8B: Basic NF1
Chair: David Ingram, MD, Indiana University
|
8:00 pm - 8:15 pm:
|
Monocytes/macrophages are the primary effectors of Nf1 +/- vaso-occlusive disease
|
|
8:15 pm - 8:30 pm: |
Conditional inactivation of Pten and Nf1 in Schwann cells results in extremely rapid high-grade peripheral nerve sheath tumor development
Vincent Keng, PhD, University of Minnesota Masonic Cancer Center |
|
8:30 pm - 8:45 pm: |
Identification of a novel modifier cooperating with NF1 in tumorigenesis
Thomas De Raedt, PhD, Brigham and Women's Hospital and Harvard Medical School |
|
8:45 pm - 9:00 pm: |
A novel mechanism for Spred1 regulation of the Ras/MAPK pathway
Irma Rangel-Alarcon, University of California, San Francisco |
|
9:00 pm - 9:15 pm: |
Role of EMT-related transcriptional factors in development of neurofibromas
Hideyuki Saya, Keio University School of Medicine |
|
9:15 pm - 9:30 pm: |
Elucidating the biological role of NF1 in sporadic cancer
Ophelia Maertens, PharmD, PhD, Brigham and Women's Hospital and Harvard Medical School |
|
9:30 pm - 11:00 pm: |
Cocktail Evening/Karaoke Night |
Monday, June 13
|
7:00 am - 8:00 am:
|
Breakfast
|
SESSION 9: The Role of NF1 in the Brain
Chairs: Maria Acosta, MD, Children’s National Medical Center; and Debra Mayes, PhD, Cincinatti Children's Hospital
|
8:00 am - 8:30 am:
|
The NF1 Cognitive Phenotype: Lessons from the human model
|
|
8:30 am - 9:00 am: |
How loss of neurofibromin in oligodendrocytes affects the brain
Debra Mayes, Ph.D., Cincinnati Children’s Hospital Medical
Center |
|
9:00 am - 9:30 am: |
Critical roles of OPCs in gliomagenesis
Hui Zong, PhD, University of Oregon |
|
9:30 am - 10:00 am: |
Preclinical analysis of the RAS pathway and neurofibroma
Nancy Ratner, PhD, Cincinnati Children's Hospital Medical Center |
|
10:00 am - 10:15 am: |
General Discussion |
|
10:15 am - 10:45 am: |
Refreshment Break
|
SESSION 10: Keynote Presentation
|
10:45 am - 11:45 am:
|
Next generation modeling in the mouse, from individuals to populations
Keynote: David Threadgill, PhD, University of North Carolina School of Medicine
|
|
11:45 am - 3:00 pm:
|
Lunch and Afternoon on your own
|
|
1:00 pm - 2:30 pm: |
International Soccer Game at Softball Field at Phil Baux Park |
SESSION 11: Panel Discussion 2: Long-Term Hearing Preservation in NF2. What is the Best Option?
Moderator: Michel Kalamarides, MD, PhD, Universite Paris 7, France
Panelists: Michael Link, MD, Mayo Clinic; Scott Plotkin, MD, PhD, Massachusetts General Hospital;
and Derald Brackmann, MD, House Ear Institute
3:00 pm - 4:30 pm
SESSION 12: How Preclinical NF Mouse Models Inform Human Clinical Trials
Chairs: Roger Packer, MD, Children’s National Medical Center; and Karen Cichowski, PhD,
Harvard Cancer Center
|
4:30 pm - 4:35 pm: |
NF1: A Personal Perspective: Benjamin Ellis |
|
4:35 pm - 4:55 pm:
|
Targeting Ras Effectors in NF1-Deficient Leukemia Models
|
|
4:55 pm - 5:15 pm: |
Use of Krox20; Nf1flox/- mice and PET imaging as an intermediate throughput screen to test experimental therapeutics
Wade Clapp, MD, Indiana University |
|
5:15 pm - 5:35 pm: |
Man or mouse? The limitations of preclinical testing
Scott Plotkin, MD, PhD, Massachusetts General Hospital |
|
5:35 pm - 5:55 pm: |
Preclinical models and clinical trials a two way road
Brigitte Widemann, MD, National Cancer Institute |
|
5:55 pm - 6:15 pm: |
Of Mice and Men: Mouse Models in the Development of Molecular Targeted Therapies for Human Cancer
Matthias Karajannis, MD, New York University |
|
6:15 pm - 6:30 pm: |
General Discussion |
|
6:30 pm - 8:00 pm:
|
Dinner on your own |
SESSION 13: Poster Session 2: Clinical Aspects of Neurofibromatosis
Judges: Scott Plotkin, MD, PhD, Massachusetts General Hospital; Maria Acosta, MD,
Children's National Medical Center; Dusica Babovic, MD, Mayo Clinic; and
Elizabeth Schorry, MD, Cincinnati Children's Hospital Medical Center
8:00 pm - 9:30 pm
Tuesday, June 14
|
7:00 am - 8:00 am:
|
Breakfast
|
SESSION 14: Concurrent Abstract Platform Presentations
SESSION 14A: Clinical NF1
Chair: Ludwine Messiaen, PhD, University of Alabama; and Dusica Babovic-Vuksanovic, MD, Mayo Clinic
|
8:00 am - 8:15 am:
|
Neurofibromatosis, type 1: Genetic Modifiers of Tumor Burden
Fawn Leigh, MD, Massachusetts General Hospital and Harvard Medical School
|
|
8:15 am - 8:30 am: |
Phase 2 trial of cediranib for NF1 plexiform and/or paraspinal neurofibromas
Dusica Babovic-Vuksanovic, MD, Mayo College of Medicine |
|
8:30 am - 8:45 am: |
Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients
Kimberly Jett, University of British Columbia, Canada |
|
8:45 am - 9:00 am: |
Phase 2 Pilot Study of Imatinib in Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas (PN)
Kent Robertson, MD, PhD, Indiana University School of Medicine |
|
9:00 am - 9:15 am: |
Lovastatin normalizes the brain spontaneous low-frequency fluctuations in children with Neurofibromatosis type 1
Maria Acosta, MD, Children's National Medical Center |
|
9:15 am - 9:30 am: |
Treatment of Progressive Hyopothalamic/Optic Pathway Gliomas in Children with NF1: a Report from the Children's Oncology Group (COG)
Joann Ater, MD, UT MD Anderson Cancer Center |
SESSION 14B: Basic NF1 & NF2
Chair: Oliver Hanemann, MD, PhD, University of Plymouth, United Kingdom; and Olli Carpen, MD, PhD,
University of Turku, Finland
|
8:00 am - 8:15 am:
|
Drosophila Alk Receptor Tyrosine Kinase controls Neurofibromin-dependent Growth and Learning; a novel therapeutic target in NF1?
|
|
8:15 am - 8:30 am: |
TC21 is a crucial mediator of TGF-beta signaling in NF tumorigenesis
Deanna Patmore, Cincinnati Children's Hospital Medical Center |
|
8:30 am - 8:45 am: |
Merlin plays important roles during mouse mammary gland development and tumorigenesis
Jie Huang, MD, PhD, The Ohio State University and Nationwide Children's Hospital |
|
8:45 am - 9:00 am: |
Synergy of Nf2 and Cdkn2ab loss promoting meningioma progression in mice
Matthieu Peyre, MD, Hopital Beaujon, France |
|
9:00 am - 9:15 am: |
AR-42 and AR-12 Potently Inhibit the Growth of NF2-deficient Human Meningiomas
Sarah Burns, The Ohio State University and Nationwide Children's Hospital |
|
9:15 am - 9:30 am: |
Characterization of the role of CRL4DCAF1, an E3 ubiquitin ligase, in the Hippo tumor suppressor pathway
Wei Li, PhD, Memorial Sloan-Kettering Cancer Center |
SESSION 15: Mesenchymal Defects in NF
Chair: David Viskochil, MD, PhD, University of Utah
|
9:45 am - 10:15 pm:
|
Insights into NF1 Cardiovascular Disease from Mouse Models and Human Clinical Trials
|
|
10:15 am - 10:45 pm: |
Exploring the Molecular Basis for Sexual Disparity in Pediatric Brain Tumors using Models of NF1-associated Gliomagenesis
Josh Rubin, MD, PhD, Washington University |
SESSION 16: Emerging Targets in NF1
Chairs: Peggy Wallace, PhD, University of Florida; and Meena Upadhyaya, PhD, University of Cardiff, United Kingdom
|
11:15 am - 11:30 am:
|
Drug-induced autophagy as a mechanism of therapeutic resistance in MPNST
Dina Lev, MD, The University of Texas |
|
11:30 am - 11:45 am: |
Genomic Analysis of Peripheral Nervous System Tumors in NF1: Detecting Genes Involoved in Tumor Predispostion and Progression
Eduard Serra, PhD, Institut de Medicina Predictiva I Personalitzada del Cancer, Spain |
|
11:45 am - 12:15 pm: |
Exploiting cancer cell vulnerabilities to develop a combination therapy for MPNSTs
Karen Cichowski, PhD, Harvard Cancer Center |
|
Conference Agenda
